학술논문
Meropenem/colistin versus meropenem/ampicillin–sulbactam in the treatment of carbapenem-resistant pneumonia
Document Type
Article
Author
Source
Journal of Comparative Effectiveness Research; September 2018, Vol. 7 Issue: 9 p901-911, 11p
Subject
Language
ISSN
20426305; 20426313
Abstract
Aim:Efficacy of colistin and ampicillin–sulbactam have not been compared in treatment of ventilator-associated pneumonia due to A. baumannii. Efficacy of colistin and ampicillin–sulbactam in combination with meropenem were compared in treatment of ventilator-associated pneumonia due to carbapenem-resistant A. baumannii. Method:47 patients with ventilator-associated pneumonia due to carbapenem-resistant A. baumanniiwere randomized to receive meropenem/colistin or meropenem/ampicillin–sulbactam for 14 days. Clinical and microbiological responses and 28-day mortality were considered as outcomes. Results:Clinical response (75 vs 69.6; p 0.75) and microbial eradication (87.50 vs 91.3; p 0.59) were comparable between meropenem/colistin and meropenem/ampicillin–sulbactam groups, respectively. Conclusion:In this study, clinical and microbiological response were comparable between the meropenem/colistin and meropenem/ampicillin–sulbactam groups.